App-Quantinova.ai

Patterns of Family History of Cancer in Adults with Hematologic Malignancies

Karen Seiter - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Relationship between LDH and Mg in Monitoring of Hematological and Non-Hematological Malignant Diseases

Aurelian Udristioiu - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The 15 Year Long-Term Survival of Patients with Chronic Myeloid Leukaemia from 35 Regions of Russian Federation: A Follow up of a Multicenter Observation Study Eutos Osp Initiated By European Leukemia NET

Olga V. Lazareva - American Society of Hematology (ASH) , 2021

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Imatinib

The Thymus Is Critical for Adult Immune Function

Kameron Kooshesh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fuldazin

Combined Inhibition of CDK2 and BCL2 Overrides Resistance to Targeting BTK and CDK4/6 in Mantle Cell Lymphoma Therapy

Haya Y. Al-Ansari - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Palbociclib

A Novel Method for Efficient cGMP Production of Natural Killer Cells from Clonal Master Induced Pluripotent Stem Cells for Next Generation, Off-the-Shelf Cancer Immunotherapy

Davide Bernareggi - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

L-Tyrosine

High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas

Yago Nieto - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

Breast cancer

Gemcitabine

Risk Factors Beyond Chemo-Radiotherapy Exposure for Therapy-Related Myelodysplastic Syndrome (tMDS) and Acute Myeloid Leukemia (tAML) Development in Breast Cancer Survivors: A 15-Year SEER-Medicare Analysis

Abhay Singh Singh - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Breast cancer

Filgrastim

Anagrelide Represents a Potential Therapeutic Therapy for Acute Myeloid Leukemia Cells Based on Phosphodiesterase 3A Expression

Chenwei Yang - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

Anagrelide hydrochloride

Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Bing Z Carter - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Venetoclax

B7-H3 Trike Enhances Killing of Myeloid Derived Suppressor Cells in Multiple Myeloma

Aimee Merino - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Breast cancer

GM-CSF

Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Yannan Jia - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Breast cancer

Navitoclax

Overexpression of Oncogenic Inhibitory-ASPP (inhibitor of apoptosis stimulating protein of p53) Results in Therapy Resistance and Adverse Outcome in AML

Marcus Matthias Schittenhelm - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Daunorubicin

Targeting RSK1-Mediated Dependency and Inflammation in Myeloid Malignancies

Tim Kong - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Ruxolitinib phosphate

GPC-100 Is a Novel CXCR4 Inhibitor That Leads to Improved in Vitro Potency and In Vivo Efficacy in Stem Cell Mobilization When Combined with a Beta-Blocker

Juan Jose Fung - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Norepinephrine bitartrate

Characterization of a Cyclic Dinucleotide Metabolic Switch to Fuel Antitumor Immunity

Jeremy A. Meier - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Interferon

Two Randomized Controlled Trials of Romiplostim for Chemotherapy-Induced Thrombocytopenia in Patients with Solid Tumors

Hanny Al-Samkari - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Breast cancer

Carboplatin

Cancer Cells and Platelets Have a Synergistic Role on the Acceleration of Clot Formation and Fibrin Polymerization. a Thromboelastometric Study

Elisabeth Mbemba - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Doxorubicin

Integrated Gene Expression Analysis Identifies ETS2 Involved in Oncogene Induced Senescence to be Associated with Poor Outcome in Paediatric AML

Phani Krishna Parcha - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Breast cancer

Cytarabine liposomal

Clinical Features and Prognosis of Double Primary Malignant Neoplasms in Patients with Non-Hodgkin Lymphoma

Zhumei Zhan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Breast cancer

N/A

Filters

14023 Abstracts